News
MRNA
60.57
+1.27%
0.76
Trump Trade: President signs EO to split up of childhood vaccines
TipRanks · 19h ago
Trump signs EO to split up of childhood vaccines, Bloomberg reports
TipRanks · 1d ago
Trump executive order set to make major changes to childhood vaccines schedule
Seeking Alpha · 1d ago
Market breadth strengthens: Equal-weight S&P 500 pulls ahead of market-weight index
Seeking Alpha · 1d ago
Moderna: I'm Still On Sell, But Here's What Would Change My Mind
Seeking Alpha · 1d ago
Weekly Report: what happened at MRNA last week (0803-0807)?
Weekly Report · 1d ago
Is Moderna (MRNA) Quietly Redefining Its Pipeline With Canada’s Bundibugyo Ebola Trial Green Light?
Simply Wall St · 2d ago
Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus
Seeking Alpha · 2d ago
Moderna (MRNA) Q2 2026 Earnings Call Transcript
The Motley Fool · 4d ago
Moderna Inc. Stock Climbs 9.9%, Outperforms Peers
Dow Jones · 4d ago
Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data
NASDAQ · 4d ago
Moderna (MRNA) Wins FDA Flu Vaccine Approval On Questions Over Whether The Stock Is Fully Valued
Simply Wall St · 4d ago
Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones
NASDAQ · 4d ago
Trump Trade: U.S. issues 15% duty on products made from polysilicon
TipRanks · 4d ago
Trump admin plans to issue executive order on vaccines, autism, Bloomberg says
TipRanks · 4d ago
Trump weighs executive order on vaccines and autism - report
Seeking Alpha · 5d ago
Moderna Inc. Stock Sheds 4.3%, Underperforms Peers
Dow Jones · 5d ago
Moderna Just Got FDA Clearance for Flu Vaccine. The Stock Is Sliding.
Barron‘s · 5d ago
Midday Fly By: SanDisk, Western Digital slide despite Q4 beats
TipRanks · 5d ago
Moderna Stock Slips Despite FDA Approval for New Flu Shot mFlusiva
TipRanks · 5d ago
More
Webull provides a variety of real-time MRNA stock news. You can receive the latest news about Moderna through multiple platforms. This information may help you make smarter investment decisions.
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).